CRISPR Therapeutics (NASDAQ:CRSP), Analyst Ratings, Price Targets, Predictions

The latest price target for CRISPR Therapeutics (NASDAQ: CRSP) was reported by Oppenheimer on June 23, 2022. The analyst firm set a price target for $122.00 expecting CRSP to rise to within 12 months (a possible 78.73% upside). 28 analyst firms have reported ratings in the last year.

The latest analyst rating for CRISPR Therapeutics (NASDAQ: CRSP) was provided by Oppenheimer, and CRISPR Therapeutics maintained their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on June 23, 2022 so you should expect the next rating to be made available sometime around June 23, 2023.

While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a maintained with a price target of $150.00 to $122.00. The current price CRISPR Therapeutics (CRSP) is trading at is $68.26, which is out of the analyst’s predicted range.